Sanofi (SNYNF) and Regeneron have announced that a pivotal Phase 3 trial of Dupixent (dupilumab) met its primary and all key secondary endpoints in children …
Shares in Regeneron advanced 3.5% in Wednesday’s extended market session after the company filed for Emergency Use Authorization (EUA) with the US Food …
Shares in Regeneron Pharmaceuticals are advancing 4.4% in Wednesday’s pre-market trading after the company disclosed that its investigational two-antibody cocktail, REGN-COV2, lowered viral …
Sanofi (SNYNF) and Regeneron have announced positive pivotal trial data for the investigational use of PD-1 inhibitor Libtayo (cemiplimab) in first-line locally advanced …
Regeneron Pharmaceuticals (REGN) and Sanofi have announced new results from a Dupixent (dupilumab) Phase 3 open-label extension trial that showed the safety and efficacy …
Regeneron Pharma (REGN) and Roche (RHHBY) have announced that they will work together to develop, manufacture and distribute REGN-COV2, Regeneron’s investigational anti-viral antibody …
Regeneron Pharmaceuticals (REGN) has now announced the pricing of an underwritten offering of $1.250 billion aggregate principal amount of senior unsecured notes due …
Regeneron Pharmaceuticals Inc (REGN) has revealed that its investigational COVID-19 antibody drug combination REGN-COV2 both prevented and treated the disease in monkeys and …
Regeneron Pharmaceuticals, Inc (REGN) announced on Tuesday that it has won a $450 million contract with the U.S government to manufacture and supply …
French drugmaker Sanofi (SNYNF) has received regulatory approval in China for its Dupixent drug, which it is developing together with Regeneron Pharmaceuticals, Inc …
